scholarly journals Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus

10.5772/20616 ◽  
2011 ◽  
Author(s):  
Athanasia K. ◽  
Marina S. ◽  
Stavros I.
Keyword(s):  
Diabetes Mellitus ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Treatment Of Diabetes

scholarly journals Differential diagnosis and treatment of diabetes mellitus associated with Cushig’s disease

2017 ◽  
Vol 14 (2) ◽  
pp. 53-58
Author(s):  
Larisa K. Dzeranova ◽  
Ekaterina E. Bibik ◽  
Ekaterina A. Pigarova ◽  
Taras S. Panevin ◽  
Andrey Yu. Grigor'ev
Keyword(s):  
Diabetes Mellitus ◽  
Differential Diagnosis ◽  
Positive Impact ◽  
Dipeptidyl Peptidase ◽  
Diagnosis And Treatment ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Treatment Of Diabetes

Diabetes mellitus associated with endogenic hypercortisolism is one of the most frequent symptoms of Cushings disease and may mask other implications. Achievement of the diseases remission not always leads to complete involution of its complications. The new glucose-lowering drugs can exert a complex positive impact in patients with hypercortisolemic comorbidities. To treat diabetes mellitus associated with the central hypercortisolism groups of dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter-2 inhibitors should be taken into account.

scholarly journals Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus

Antioxidants ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 233
Author(s):  
Elisabetta Bigagli ◽  
Cristina Luceri ◽  
Ilaria Dicembrini ◽  
Lorenzo Tatti ◽  
Francesca Scavone ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Propensity Score ◽  
Oxidative Damage ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

Pre-clinical studies suggested potential cardiovascular benefits of dipeptidyl peptidase-4 inhibitors (DPP4i), however, clinical trials showed neither beneficial nor detrimental effects in patients with type 2 diabetes mellitus (T2DM). We examined the effects of DPP4i on several circulating oxidative stress markers in a cohort of 32 T2DM patients (21 males and 11 post-menopausal females), who were already on routine antidiabetic treatment. Propensity score matching was used to adjust demographic and clinical characteristics between patients who received and who did not receive DPP4i. Whole-blood reactive oxygen species (ROS), plasma advanced glycation end products (AGEs), advanced oxidation protein products (AOPP), carbonyl residues, as well as ferric reducing ability of plasma (FRAP) and leukocyte DNA oxidative damage (Fpg sites), were evaluated. With the exception of Fpg sites, that showed a borderline increase in DPP4i users compared to non-users (p = 0.0507), none of the biomarkers measured was affected by DPP4i treatment. An inverse correlation between estimated glomerular filtration rate and AGEs (p < 0.0001) and Fpg sites (p < 0.05) was also observed. This study does not show any major effect of DPP4i on oxidative stress, assessed by several circulating biomarkers of oxidative damage, in propensity score-matched cohorts of T2DM patients.

The role of dipeptidyl peptidase-4 inhibitors

BMJ ◽  
2012 ◽  
Vol 344 (mar12 1) ◽  
pp. e1213-e1213 ◽  
Author(s):  
D. Lasserson ◽  
J. Mant
Keyword(s):  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document